Direct oral anticoagulants in antiphospholipid syndrome: a real life case series
Direct oral anticoagulants in antiphospholipid syndrome: a real life case series
复制标题
DOI：
10.1177/0961203315624555
复制
发表时间：
2016-05-01
期刊：
影响因子：
2.6
通讯作者：
Tobon, G. J.
中科院分区：
文献类型：
--
作者：
Betancur, J. F.;Bonilla-Abadia, F.;Tobon, G. J.
目的本研究的目的是描述一个病例系列的原发性或继发性抗磷脂综合征（APS）患者直接口服抗凝剂（DOAC）治疗。患者和方法回顾性分析2012年1月至2015年5月期间8例血栓性原发性或继发性APS患者直接口服抗凝剂（DOAC）治疗的临床图表。结果平均年龄为4514.36岁（27-69岁）。4例患者发生继发性APS（50%）。所有患者最初均接受华法林治疗，平均时间为70.87 ± 57.32个月（范围17-153个月）。抗凝变化定义为5例患者（62.5%）血栓复发，其他3例患者危及生命的出血。7例患者（87.5%）接受利伐沙班治疗，1例患者（12.5%）接受阿哌沙班治疗。DOAC的平均随访期为19 ± 10.06个月（范围2-36个月）。有没有复发的血栓形成的时间datacollection.Conclusions尽管不是标准的治疗APS，我们建议DOACs作为一个合理的选择，为管理这种诊断的患者。进一步的干预性临床研究是必要的，可能的标准化，这种治疗在APS患者。
Aim The aim of this study was to describe a case series of patients with primary or secondary antiphospholipid syndrome (APS) treated with direct oral anticoagulants (DOACs).Patients and methods Clinical charts of eight patients with thrombotic primary or secondary APS treated with direct oral anticoagulants (DOACs) between January 2012 and May 2015 were reviewed.Results The mean age was 4514.36 (range 27-69 years). Four patients had secondary APS (50%). All patients were initially treated with warfarin by a mean time of 70.87 +/- 57.32 months (range 17-153 months). Changes in anticoagulation were defined by recurring thrombosis in five patients (62.5%) and life-threatening bleeding in the other three cases. Seven patients (87.5%) received rivaroxaban treatment and one patient (12.5%) apixaban. The mean follow-up period with DOACs was 19 +/- 10.06 months (range 2-36 months). There was no recurrence of thrombosis by the time of data collection.Conclusions Despite not being the standard treatment in APS, we propose DOACs as a rational alternative for the management of patients with this diagnosis. Further interventional clinical studies are necessary for possible standardization of this therapy in APS patients.